Questioning the “Why”: CDC committee weighs halting routine Hepatitis B vaccine for babies A key CDC advisory committee is debating a potential delay to the hepatitis B vaccine birth dose. Critics argue the vaccine was licensed based on flawed, short-duration clinical trials lacking proper safety data. Significant safety concerns are raised, including links to neurodevelopmental disorders and thousands of reported adverse events. The vaccine’s necessity for newborns is questioned, as hepatitis B is primarily an adult-acquired, bloodborne infection. The debate highlights broader issues of pharmaceutical influence, informed consent and childhood vaccine policy. In a significant move, a key committee advising the U.S. Centers…

Newswire

Features

The Latest